Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kusaba, H.
Right arrow Articles by Saijo, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kusaba, H.
Right arrow Articles by Saijo, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 32:43-47 (2002)
© 2002 Foundation for Promotion of Cancer Research

Phase I/II Study of 3-Week Cycle Cisplatin–Gemcitabine in Advanced Non-small Cell Lung Cancer

Hitoshi Kusaba, Tomohide Tamura, Tatsu Shimoyama, Katsuyuki Hotta, Akira Inoue, Hiroshi Nokihara, Yutaka Ueda, Yoshiko Akiyama, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Tetsuro Kodama and Nagahiro Saijo+

Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan

Background: The combination of cisplatin and gemcitabine is one of the most active chemotherapy regimens against non-small cell lung cancer. However, the optimum schedule for this combination has not been determined. This study was performed to determine the maximum tolerated dose of gemcitabine combined with cisplatin in a 3-week cycle regimen and to observe safety and efficacy for Japanese patients with advanced non-small cell lung cancer.

Methods: 80 mg/m2 of cisplatin on day 1 and escalated doses of gemcitabine on days 1 and 8 were administered every 3 weeks to patients with previously untreated, advanced non-small cell lung cancer. The initial dose of gemcitabine was 1000 mg/m2 and was escalated in 250 mg/m2 increments.

Results: Twenty-four patients were enrolled between March and December 2000. In total, 64 courses were given. The main toxicities were neutropenia, thrombocytopenia and hepatotoxicity. The maximum tolerated dose was determined to be 1500 mg/m2 of gemcitabine combined with 80 mg/m2 of cisplatin. Nine of 24 patients (37.5%) achieved a partial response.

Conclusion: This study demonstrates that the combination of cisplatin and gemcitabine repeated every three weeks is tolerable for Japanese patients with advanced non-small cell lung cancer. We determined 1250 mg/m2 of gemcitabine combined with 80 mg/m2 of cisplatin to be the recommended dose.

+ For reprints and all correspondence: Tomohide Tamura, Division of Internal Medicine, National Cancer Center Hospital, 1–1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.